Understanding and managing metabolic dysfunction in Amyotrophic Lateral Sclerosis

References

• Bjornevik K, O’Reilly EJ, Berry JD, et al. Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis. Neurology. 2019;92(18):e2081–e2088.
   PubMed Web of Science ®Google Scholar
• Verber NS, Shepheard SR, Sassani M, et al. Biomarkers in motor neuron disease: a state of the art review. Front Neurol. 2019;10:291.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13(11):1127–1138.
   PubMed Web of Science ®Google Scholar
• Chio A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118–130.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9(11):617–628.
   PubMed Web of Science ®Google Scholar
• Brito MD, da Silva GFG, Tilieri EM, et al. Metabolic alteration and amyotrophic lateral sclerosis outcome: a systematic review. Front Neurol. 2019;10:1205.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Pradat PF, Ludolph AC, et al. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10(1):75–82.
   PubMed Web of Science ®Google Scholar
• Kirk SE, Tracey TJ, Steyn FJ, et al. Biomarkers of metabolism in amyotrophic lateral sclerosis. Front Neurol. 2019;10:191.
   PubMed Web of Science ®Google Scholar
• Lanznaster D, de Assis DR, Corcia P, et al. Metabolomics biomarkers: a strategy toward therapeutics improvement in ALS. Front Neurol. 2018;9:1126.
   PubMed Web of Science ®Google Scholar
• Madji Hounoum B, Blasco H, Coque E, et al. The metabolic disturbances of motoneurons exposed to glutamate. Mol Neurobiol. 2018;55(10):7669–7676.
   PubMed Web of Science ®Google Scholar
• Madji Hounoum B, Mavel S, Coque E, et al. Wildtype motoneurons, ALS-Linked SOD1 mutation and glutamate profoundly modify astrocyte metabolism and lactate shuttling. Glia. 2017;65(4):592–605.
   PubMed Web of Science ®Google Scholar
• Vandoorne T, De Bock K, Van Den Bosch L. Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathol. 2018;135(4):489–509.
   PubMed Web of Science ®Google Scholar
• Trostchansky A. Overview of lipid biomarkers in Amyotrophic Lateral Sclerosis (ALS). Adv Exp Med Biol. 2019;1161:233–241.
   PubMed Web of Science ®Google Scholar
• Browne SE, Yang L, DiMauro JP, et al. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol Dis. 2006;22(3):599–610.
   PubMed Web of Science ®Google Scholar
• Tefera TW, Borges K. Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis. J Cereb Blood Flow and Metab. 2019;39(9):1710–1724.
   PubMed Web of Science ®Google Scholar
• Du Y, Wen Y, Guo X, et al. A genome-wide expression association analysis identifies genes and pathways associated with amyotrophic lateral sclerosis. Cell Mol Neurobiol. 2018;38(3):635–639.
   PubMed Web of Science ®Google Scholar
• Diaz-Ortiz ME, Chen-Plotkin AS. Omics in neurodegenerative disease: hope or Hype? Trends Genet. 2020;36(3):152–159.
   PubMed Web of Science ®Google Scholar
• Hedl TJ, San Gil R, Cheng F, et al. Proteomics approaches for biomarker and drug target discovery in ALS and FTD. Front Neurosci. 2019;13:548.
   PubMed Web of Science ®Google Scholar
• Ferraiuolo L, Heath PR, Holden H, et al. Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J Neurosci. 2007;27(34):9201–9219.
   PubMed Web of Science ®Google Scholar
• Kirby J, Ning K, Ferraiuolo L, et al. Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain. 2011;134(Pt 2):506–517.
   PubMedGoogle Scholar
• Blasco H, Patin F, Madji Hounoum B, et al. Metabolomics in amyotrophic lateral sclerosis: how far can it take us? Eur J Neurol. 2016;23(3):447–454.
   PubMed Web of Science ®Google Scholar
• Blasco H, Vourc’h P, Pradat PF, et al. Further development of biomarkers in amyotrophic lateral sclerosis. Expert Rev Mol Diagn. 2016;16(8):853–868.
   PubMed Web of Science ®Google Scholar
• Veyrat-Durebex C, Bris C, Codron P, et al. Metabo-lipidomics of fibroblasts and mitochondrial-endoplasmic reticulum extracts from ALS patients shows alterations in purine, pyrimidine, energetic, and phospholipid metabolisms. Mol Neurobiol. 2019;56(8):5780–5791.
   PubMed Web of Science ®Google Scholar
• Desport JC, Preux PM, Magy L, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001;74(3):328–334.
   PubMed Web of Science ®Google Scholar
• Bauckneht M, Lai R, Miceli A, et al. Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis: a computational approach to [18F]-fluorodeoxyglucose PET/CT images. EJNMMI Res. 2020;10(1):23.
   PubMed Web of Science ®Google Scholar
• Bouscary A, Quessada C, Mosbach A, et al. Ambroxol hydrochloride improves motor functions and extends survival in a mouse model of familial amyotrophic lateral sclerosis. Front Pharmacol. 2019;10:883.
   PubMed Web of Science ®Google Scholar
• Desport JC, Torny F, Lacoste M, et al. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis. 2005;2(3–4):202–207.
   PubMed Web of Science ®Google Scholar
• Kasarskis EJ, Neville HE. Management of ALS: nutritional care. Neurology. 1996;47(4 Suppl 2):S118–120.
   PubMed Web of Science ®Google Scholar
• Bouteloup C, Desport JC, Clavelou P, et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009;256(8):1236–1242.
   PubMed Web of Science ®Google Scholar
• Funalot B, Desport JC, Sturtz F, et al. High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10(2):113–117.
   PubMed Web of Science ®Google Scholar
• O’Reilly EJ, Wang H, Weisskopf MG, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2012 Oct 29, 14(3):205–211.
   PubMedGoogle Scholar
• O’Reilly EJ, Bjornevik K, Furtado JD, et al. Prediagnostic plasma polyunsaturated fatty acids and the risk of amyotrophic lateral sclerosis. Neurology. 2020;94(8):e811–e819.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Nakayama Y, Matsuda C, et al. Prognostic significance of body weight variation after diagnosis in ALS: a single-centre prospective cohort study. J Neurol. 2019;266(6):1412–1420.
   PubMed Web of Science ®Google Scholar
• Moglia C, Calvo A, Grassano M, et al. Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry. 2019;90(6):666–673.
   PubMed Web of Science ®Google Scholar
• Dardiotis E, Siokas V, Sokratous M, et al. Body mass index and survival from amyotrophic lateral sclerosis: A meta-analysis. Neurol Clin Pract. 2018;8(5):437–444.
   PubMedGoogle Scholar
• Jesus P, Fayemendy P, Nicol M, et al. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2018;25(1):97–104.
   PubMed Web of Science ®Google Scholar
• Steyn FJ, Ioannides ZA, van Eijk RPA, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry. 2018;89(10):1016–1023.
   PubMed Web of Science ®Google Scholar
• Marin B, Arcuti S, Jesus P, et al. Population-based evidence that survival in amyotrophic lateral sclerosis is related to weight loss at diagnosis. Neurodegener Dis. 2016;16(3–4):225–234.
   PubMed Web of Science ®Google Scholar
• Gonzalez de Aguilar JL, Dupuis L, Oudart H, et al. The metabolic hypothesis in amyotrophic lateral sclerosis: insights from mutant Cu/Zn-superoxide dismutase mice. Biomed Pharmacother. 2005;59(4):190–196.
   PubMed Web of Science ®Google Scholar
• Gonzalez de Aguilar JL, Echaniz-Laguna A, Fergani A, et al. Amyotrophic lateral sclerosis: all roads lead to Rome. J Neurochem. 2007;101(5):1153–1160.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Oudart H, Rene F, et al. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A. 2004;101(30):11159–11164.
   PubMed Web of Science ®Google Scholar
• Fergani A, Oudart H, Gonzalez De Aguilar JL, et al. Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. J Lipid Res. 2007;48(7):1571–1580.
   PubMed Web of Science ®Google Scholar
• Lunetta C, Lizio A, Tremolizzo L, et al. Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status. J Neurol. 2018;265(12):3001–3008.
   PubMed Web of Science ®Google Scholar
• Krasnianski A, Deschauer M, Neudecker S, et al. Mitochondrial changes in skeletal muscle in amyotrophic lateral sclerosis and other neurogenic atrophies. Brain. 2005;128(Pt 8):1870–1876.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Loeffler JP. Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models. Curr Opin Pharmacol. 2009;9(3):341–346.
   PubMed Web of Science ®Google Scholar
• Mattson MP, Cutler RG, Camandola S. Energy intake and amyotrophic lateral sclerosis. Neuromolecular Med. 2007;9(1):17–20.
   PubMed Web of Science ®Google Scholar
• Wills AM, Hubbard J, Macklin EA, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;383(9934):2065–2072.
   PubMed Web of Science ®Google Scholar
• Ludolph AC, Dorst J, Dreyhaupt J, et al. Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Ann Neurol. 2020;87(2):206–216.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004–1009.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hirayama T, Takazawa T, et al. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51(12):1501–1508.
   PubMed Web of Science ®Google Scholar
• Chio A, Calvo A, Ilardi A, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73(20):1681–1685.
   PubMed Web of Science ®Google Scholar
• Kim SM, Kim H, Kim JE, et al. Amyotrophic lateral sclerosis is associated with hypolipidemia at the presymptomatic stage in mice. PLoS One. 2011;6(3):e17985.
   PubMed Web of Science ®Google Scholar
• Ahmed RM, Highton-Williamson E, Caga J, et al. Lipid metabolism and survival across the frontotemporal dementia-amyotrophic lateral sclerosis spectrum: relationships to eating behavior and cognition. J Alzheimers Dis. 2018;61(2):773–783.
   PubMed Web of Science ®Google Scholar
• Dedic SI, Stevic Z, Dedic V, et al. Is hyperlipidemia correlated with longer survival in patients with amyotrophic lateral sclerosis? Neurol Res. 2012;34(6):576–580.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Deng J, Jaffa M, et al. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44(1):20–24.
   PubMed Web of Science ®Google Scholar
• Dorst J, Kuhnlein P, Hendrich C, et al. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258(4):613–617.
   PubMed Web of Science ®Google Scholar
• Huang R, Guo X, Chen X, et al. The serum lipid profiles of amyotrophic lateral sclerosis patients: A study from south-west China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5–6):359–365.
   PubMed Web of Science ®Google Scholar
• FernAndez-Eulate G, Ruiz-Sanz JI, Riancho J, et al. A comprehensive serum lipidome profiling of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020 May;21(3–4):252–262.
   PubMed Web of Science ®Google Scholar
• Cutler RG, Pedersen WA, Camandola S, et al. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52(4):448–457.
   PubMed Web of Science ®Google Scholar
• Blasco H, Veyrat-Durebex C, Bocca C, et al. Lipidomics reveals cerebrospinal-fluid signatures of ALS. Sci Rep. 2017;7(1):17652.
   PubMedGoogle Scholar
• Mouzat K, Chudinova A, Polge A, et al. Regulation of brain cholesterol: what role do liver x receptors play in neurodegenerative diseases? Int J Mol Sci. 2019 Aug 8;20(16):3858. DOI:10.3390/ijms20163858
   PubMed Web of Science ®Google Scholar
• Ilieva EV, Ayala V, Jove M, et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain. 2007;130(Pt 12):3111–3123.
   PubMed Web of Science ®Google Scholar
• Henriques A, Croixmarie V, Priestman DA, et al. Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase. Hum Mol Genet. 2015;24(25):7390–7405.
   PubMed Web of Science ®Google Scholar
• Valbuena GN, Cantoni L, Tortarolo M, et al. Spinal cord metabolic signatures in models of fast- and slow-progressing SOD1(G93A) amyotrophic lateral sclerosis. Front Neurosci. 2019;13:1276.
   PubMed Web of Science ®Google Scholar
• Gutner UA, Shupik MA, Maloshitskaya OA, et al. Changes in the metabolism of sphingoid bases in the brain and spinal cord of transgenic FUS(1-359) mice, a model of amyotrophic lateral sclerosis. Biochemistry (Mosc). 2019;84(10):1166–1176.
   PubMed Web of Science ®Google Scholar
• Chaves-Filho AB, Pinto IFD, Dantas LS, et al. Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis. Sci Rep. 2019;9(1):11642.
   PubMedGoogle Scholar
• Pradat PF, Bruneteau G, Gordon PH, et al. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;11(1–2):166–171. DOI:10.3109/17482960902822960
   Google Scholar
• Patin F, Baranek T, Vourc’h P, et al. Combined metabolomics and transcriptomics approaches to assess the IL-6 blockade as a therapeutic of ALS: deleterious alteration of lipid metabolism. Neurotherapeutics. 2016;13(4):905–917.
   PubMed Web of Science ®Google Scholar
• Tefera TW, Borges K. Metabolic dysfunctions in amyotrophic lateral sclerosis pathogenesis and potential metabolic treatments. Front Neurosci. 2016;10:611.
   PubMed Web of Science ®Google Scholar
• Guo Z, Kindy MS, Kruman I, et al. ALS-linked Cu/Zn-SOD mutation impairs cerebral synaptic glucose and glutamate transport and exacerbates ischemic brain injury. J Cereb Blood Flow and Metab. 2000;20(3):463–468.
   PubMed Web of Science ®Google Scholar
• Cistaro A, Valentini MC, Chio A, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging. 2012;39(2):251–259.
   PubMed Web of Science ®Google Scholar
• Stallings NR, Puttaparthi K, Dowling KJ, et al. TDP-43, an ALS linked protein, regulates fat deposition and glucose homeostasis. PLoS One. 2013;8(8):e71793.
   PubMed Web of Science ®Google Scholar
• Vallee A, Lecarpentier Y, Guillevin R, et al. Aerobic glycolysis in amyotrophic lateral sclerosis and Huntington’s disease. Rev Neurosci. 2018;29(5):547–555.
   PubMed Web of Science ®Google Scholar
• Pennuto M, Pandey UB, Polanco MJ. Insulin-like growth factor 1 signaling in motor neuron and polyglutamine diseases: from molecular pathogenesis to therapeutic perspectives. Front Neuroendocrinol. 2020 Apr;57:100821. DOI:10.1016/j.yfrne.2020.100821
   Google Scholar
• Allen SP, Rajan S, Duffy L, et al. Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis. Neurobiol Aging. 2014;35(6):1499–1509.
   PubMed Web of Science ®Google Scholar
• Valbuena GN, Rizzardini M, Cimini S, et al. Metabolomic analysis reveals increased aerobic glycolysis and amino acid deficit in a cellular model of amyotrophic lateral sclerosis. Mol Neurobiol. 2016;53(4):2222–2240.
   PubMed Web of Science ®Google Scholar
• Ferraiuolo L, Higginbottom A, Heath PR, et al. Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain. 2011;134(Pt 9):2627–2641.
   PubMedGoogle Scholar
• Allen SP, Hall B, Woof R, et al. C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. Brain. 2019;142(12):3771–3790.
   PubMedGoogle Scholar
• Miller A, Adeli K. Dietary fructose and the metabolic syndrome. Curr Opin Gastroenterol. 2008;24(2):204–209.
   PubMed Web of Science ®Google Scholar
• Vandoorne T, Veys K, Guo W, et al. Differentiation but not ALS mutations in FUS rewires motor neuron metabolism. Nat Commun. 2019;10(1):4147.
   PubMedGoogle Scholar
• Deng J, Wang P, Chen X, et al. FUS interacts with ATP synthase beta subunit and induces mitochondrial unfolded protein response in cellular and animal models. Proc Natl Acad Sci U S A. 2018;115(41):E9678–E9686.
   PubMed Web of Science ®Google Scholar
• Araki K, Araki A, Honda D, et al. TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. J Clin Invest. 2019;130:3578–3593.
   Google Scholar
• Yip PK, Pizzasegola C, Gladman S, et al. The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis. PLoS One. 2013;8(4):e61626.
   PubMed Web of Science ®Google Scholar
• Henriques A, Huebecker M, Blasco H, et al. Inhibition of beta-glucocerebrosidase activity preserves motor unit integrity in a mouse model of amyotrophic lateral sclerosis. Sci Rep. 2017;7(1):5235.
   PubMedGoogle Scholar
• Manzo E, Lorenzini I, Barrameda D, et al. Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. Elife. 2019 Jun 10;8:e45114. DOI:10.7554/eLife.45114
   PubMed Web of Science ®Google Scholar
• Wiedemann FR, Manfredi G, Mawrin C, et al. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem. 2002;80(4):616–625.
   PubMed Web of Science ®Google Scholar
• Jung C, Higgins CM, Xu Z. Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. J Neurochem. 2002;83(3):535–545.
   PubMed Web of Science ®Google Scholar
• Mattiazzi M, D’Aurelio M, Gajewski CD, et al. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem. 2002;277(33):29626–29633.
   PubMed Web of Science ®Google Scholar
• Menzies FM, Cookson MR, Taylor RW, et al. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain. 2002;125(Pt 7):1522–1533.
   PubMedGoogle Scholar
• Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006;55(Suppl 2):S9–S15.
   PubMed Web of Science ®Google Scholar
• Veyrat-Durebex C, Corcia P, Piver E, et al. Disruption of TCA cycle and glutamate metabolism identified by metabolomics in an in vitro model of amyotrophic lateral sclerosis. Mol Neurobiol. 2016;53(10):6910–6924.
   PubMed Web of Science ®Google Scholar
• Lederer CW, Torrisi A, Pantelidou M, et al. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genomics. 2007;8:26.
   PubMed Web of Science ®Google Scholar
• Niessen HG, Debska-Vielhaber G, Sander K, et al. Metabolic progression markers of neurodegeneration in the transgenic G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Eur J Neurosci. 2007;25(6):1669–1677.
   PubMed Web of Science ®Google Scholar
• Tefera TW, Tan KN, McDonald TS, et al. Alternative fuels in epilepsy and amyotrophic lateral sclerosis. Neurochem Res. 2017;42(6):1610–1620.
   PubMed Web of Science ®Google Scholar
• Park JH, Hong YH, Kim HJ, et al. Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model. Neurosci Lett. 2007;413(3):265–269.
   PubMed Web of Science ®Google Scholar
• Esposito E, Capasso M, Di Tomasso N, et al. Antioxidant strategies based on tomato-enriched food or pyruvate do not affect disease onset and survival in an animal model of amyotrophic lateral sclerosis. Brain Res. 2007;1168:90–96.
   PubMed Web of Science ®Google Scholar
• Pellerin L, Magistretti PJ. Neuroenergetics: calling upon astrocytes to satisfy hungry neurons. Neuroscientist. 2004;10(1):53–62.
   PubMed Web of Science ®Google Scholar
• Castillo X, Rosafio K, Wyss MT, et al. A probable dual mode of action for both L- and D-lactate neuroprotection in cerebral ischemia. J Cereb Blood Flow and Metab. 2015;35(10):1561–1569.
   PubMed Web of Science ®Google Scholar
• Bigini P, Larini S, Pasquali C, et al. Acetyl-L-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons. Neurosci Lett. 2002;329(3):334–338.
   PubMed Web of Science ®Google Scholar
• Beghi E, Pupillo E, Bonito V, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(5–6):397–405.
   PubMed Web of Science ®Google Scholar
• Group AL, Fournier C, Bedlack B, et al. ALS untangled no. 20: the Deanna protocol. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(4):319–323.
   PubMed Web of Science ®Google Scholar
• Ari C, Poff AM, Held HE, et al. Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model. PLoS One. 2014;9(7):e103526.
   PubMed Web of Science ®Google Scholar
• Mochel F, Hainque E, Gras D, et al. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry. 2016;87(5):550–553.
   PubMed Web of Science ®Google Scholar
• Tefera TW, Wong Y, Barkl-Luke ME, et al. Triheptanoin protects motor neurons and delays the onset of motor symptoms in a mouse model of amyotrophic lateral sclerosis. PLoS One. 2016;11(8):e0161816.
   PubMed Web of Science ®Google Scholar
• Itoh Y, Esaki T, Shimoji K, et al. Dichloroacetate effects on glucose and lactate oxidation by neurons and astroglia in vitro and on glucose utilization by brain in vivo. Proc Natl Acad Sci U S A. 2003;100(8):4879–4884.
   PubMed Web of Science ®Google Scholar
• Miquel E, Cassina A, Martinez-Palma L, et al. Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis. PLoS One. 2012;7(4):e34776.
   PubMed Web of Science ®Google Scholar
• Palamiuc L, Schlagowski A, Ngo ST, et al. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol Med. 2015;7(5):526–546.
   PubMed Web of Science ®Google Scholar
• Martinez-Palma L, Miquel E, Lagos-Rodriguez V, et al. Mitochondrial modulation by dichloroacetate reduces toxicity of aberrant glial cells and gliosis in the SOD1G93A rat model of amyotrophic lateral sclerosis. Neurotherapeutics. 2019;16(1):203–215.
   PubMed Web of Science ®Google Scholar
• Comhaire F. Why do some ME/CFS patients benefit from treatment with sodium dichloroacetate, but others do not? Med Hypotheses. 2018;120:65–67.
   PubMed Web of Science ®Google Scholar
• Siva N. Can ketogenic diet slow progression of ALS? Lancet Neurol. 2006;5(6):476.
   PubMed Web of Science ®Google Scholar
• Veyrat-Durebex C, Reynier P, Procaccio V, et al. How can a ketogenic diet improve motor function? Front Mol Neurosci. 2018;11:15.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Lange DJ, Voustianiouk A, et al. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci. 2006;7:29.
   PubMed Web of Science ®Google Scholar
• Song W, Song Y, Kincaid B, et al. Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1alpha. Neurobiol Dis. 2013;51:72–81.
   PubMed Web of Science ®Google Scholar
• Korner S, Boselt S, Thau N, et al. Differential sirtuin expression patterns in Amyotrophic Lateral Sclerosis (ALS) Postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS? Neurodegener Dis. 2013;11(3):141–152.
   PubMed Web of Science ®Google Scholar
• Zhao W, Varghese M, Vempati P, et al. Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease. PLoS One. 2012;7(11):e49191.
   PubMed Web of Science ®Google Scholar
• Caplliure-Llopis J, Peralta-Chamba T, Carrera-Julia S, et al. Therapeutic alternative of the ketogenic mediterranean diet to improve mitochondrial activity in Amyotrophic Lateral Sclerosis (ALS): a comprehensive review. Food Sci Nutr. 2020;8(1):23–35.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Wills AM. High-fat and ketogenic diets in amyotrophic lateral sclerosis. J Child Neurol. 2013;28(8):989–992.
   PubMed Web of Science ®Google Scholar
• Carri MT, D’Ambrosi N, Cozzolino M. Pathways to mitochondrial dysfunction in ALS pathogenesis. Biochem Biophys Res Commun. 2017;483(4):1187–1193.
   PubMed Web of Science ®Google Scholar
• Cassina P, Cassina A, Pehar M, et al. Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J Neurosci. 2008;28(16):4115–4122.
   PubMed Web of Science ®Google Scholar
• Zhou ZD, Saw WT, Tan EK. Mitochondrial CHCHD-containing proteins: physiologic functions and link with neurodegenerative diseases. Mol Neurobiol. 2017;54(7):5534–5546.
   PubMed Web of Science ®Google Scholar
• Pansarasa O, Bordoni M, Drufuca L, et al. Lymphoblastoid cell lines as a model to understand amyotrophic lateral sclerosis disease mechanisms. Dis Model Mech. 2018;11:3.
   Web of Science ®Google Scholar
• Kirk K, Gennings C, Hupf JC, et al. Bioenergetic markers in skin fibroblasts of sporadic amyotrophic lateral sclerosis and progressive lateral sclerosis patients. Ann Neurol. 2014;76(4):620–624.
   PubMed Web of Science ®Google Scholar
• Konrad C, Kawamata H, Bredvik KG, et al. Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients. Mol Neurodegener. 2017;12(1):76.
   PubMedGoogle Scholar
• Ravera S, Torazza C, Bonifacino T, et al. Altered glucose catabolism in the presynaptic and perisynaptic compartments of SOD1(G93A) mouse spinal cord and motor cortex indicates that mitochondria are the site of bioenergetic imbalance in ALS. J Neurochem. 2019;151(3):336–350.
   PubMed Web of Science ®Google Scholar
• Matthews RT, Yang L, Browne S, et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998;95(15):8892–8897.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Thompson JL, Levy G, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66(2):235–244.
   PubMed Web of Science ®Google Scholar
• Tauskela JS. MitoQ–a mitochondria-targeted antioxidant. IDrugs. 2007;10(6):399–412.
   PubMedGoogle Scholar
• Miquel E, Cassina A, Martinez-Palma L, et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic Biol Med. 2014;70:204–213.
   PubMed Web of Science ®Google Scholar
• Snow BJ, Rolfe FL, Lockhart MM, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov Disord. 2010;25(11):1670–1674.
   PubMed Web of Science ®Google Scholar
• Alavian KN, Dworetzky SI, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res. 2012;1446:1–11.
   PubMed Web of Science ®Google Scholar
• Danzeisen R, Schwalenstoecker B, Gillardon F, et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther. 2006;316(1):189–199.
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011;17(12):1652–1656.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12(11):1059–1067.
   PubMed Web of Science ®Google Scholar
• Vieira FG, LaDow E, Moreno A, et al. Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PLoS One. 2014;9(12):e91608.
   PubMed Web of Science ®Google Scholar
• Adhihetty PJ, Beal MF. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med. 2008;10(4):275–290.
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999;5(3):347–350.
   PubMed Web of Science ®Google Scholar
• Andreassen OA, Jenkins BG, Dedeoglu A, et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem. 2001;77(2):383–390.
   PubMed Web of Science ®Google Scholar
• Rosenfeld J, King RM, Jackson CE, et al. Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler. 2008;9(5):266–272.
   PubMed Web of Science ®Google Scholar
• Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53(4):437–445.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology. 2004;63(9):1656–1661.
   PubMed Web of Science ®Google Scholar
• Babu S, Macklin EA, Jackson KE, et al. Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1–2):15–23.
   PubMed Web of Science ®Google Scholar
• Bordet T, Berna P, Abitbol JL, et al. Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals (Basel). 2010;3(2):345–368.
   PubMedGoogle Scholar
• Yang YM, Gupta SK, Kim KJ, et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell. 2013;12(6):713–726.
   PubMed Web of Science ®Google Scholar
• Sunyach C, Michaud M, Arnoux T, et al. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology. 2012;62(7):2346–2352.
   PubMed Web of Science ®Google Scholar
• Lenglet T, Lacomblez L, Abitbol JL, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014;21(3):529–536.
   PubMed Web of Science ®Google Scholar
• Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47(6 Suppl 4):S233–241.
   PubMed Web of Science ®Google Scholar
• Bagheri H, Ghasemi F, Barreto GE, et al. The effects of statins on microglial cells to protect against neurodegenerative disorders: a mechanistic review. Biofactors. 2020 May;46(3):309–325. DOI:10.1002/biof.1597. Epub 2019 Dec 17.
   Web of Science ®Google Scholar
• Zhang L, Tang L, Huang T, et al. life course adiposity and amyotrophic lateral sclerosis: a mendelian randomization study. Ann Neurol. 2020;87(3):434–441.
   PubMed Web of Science ®Google Scholar
• Burkhardt C, Neuwirth C, Sommacal A, et al. Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. PLoS One. 2017;12(5):e0177555.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Davidson M, Moore D, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(3):177–185.
   PubMed Web of Science ®Google Scholar
• Dorst J, Dupuis L, Petri S, et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. J Neurol. 2015;262(4):849–858.
   PubMed Web of Science ®Google Scholar
• Bond L, Ganguly P, Khamankar N, et al. A comprehensive examination of percutaneous endoscopic gastrostomy and its association with amyotrophic lateral sclerosis patient outcomes. Brain Sci. 2019 Sept 4;9(9):223. DOI:10.3390/brainsci9090223
   PubMed Web of Science ®Google Scholar
• Erber AC, Cetin H, Berry D, et al. The role of gut microbiota, butyrate and proton pump inhibitors in amyotrophic lateral sclerosis: a systematic review. Int J Neurosci. 2020 Jul;130(7):727–735. DOI:10.1080/00207454.2019.1702549. Epub 2019 Dec 23.
   PubMed Web of Science ®Google Scholar
• Fuke N, Nagata N, Suganuma H, et al. Regulation of gut microbiota and metabolic endotoxemia with dietary factors. Nutrients. 2019 Sep 23;11(10):2277. DOI:10.3390/nu11102277
   PubMed Web of Science ®Google Scholar
• Ahmed RM, Phan K, Highton-Williamson E, et al. Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. Ann Clin Transl Neurol. 2019;6(3):486–495.
   PubMed Web of Science ®Google Scholar
• Pistell PJ, Morrison CD, Gupta S, et al. Cognitive impairment following high fat diet consumption is associated with brain inflammation. J Neuroimmunol. 2010;219(1–2):25–32.
   PubMed Web of Science ®Google Scholar
• Dutheil S, Ota KT, Wohleb ES, et al. High-fat diet induced anxiety and anhedonia: impact on brain homeostasis and inflammation. Neuropsychopharmacology. 2016;41(7):1874–1887.
   PubMed Web of Science ®Google Scholar
• Vallee A, Lecarpentier Y, Guillevin R, et al. Thermodynamics in neurodegenerative diseases: interplay between canonical WNT/beta-catenin pathway-PPAR gamma, energy metabolism and circadian rhythms. Neuromolecular Med. 2018;20(2):174–204.
   PubMed Web of Science ®Google Scholar